How a High-Sensitivity Troponin 0/1-Hour Rule-Out Pathway Works

The short answer#

A 0/1-hour rule-out pathway draws blood for high-sensitivity cardiac troponin the moment a person with chest pain reaches the emergency department, then draws it again 60 minutes later. It does not judge either number in isolation. It reads the starting concentration together with the absolute change over that hour, and it uses those two figures to place the patient in one of three zones: rule-out, rule-in, or observe. A very low starting value that barely moves lands in the rule-out zone, where the chance of a missed heart attack is roughly half a percent or less. A clearly elevated value, or a sharp one-hour climb, rules a heart attack in. Everyone in between waits for more information.

Key points#

• The pathway pairs two blood draws (arrival and one hour) and interprets the baseline level and the one-hour change side by side.
• Rule-out rests on a pooled sensitivity near 99 percent and a 30-day event rate under one in a thousand in validation studies.
• Cutoffs are specific to each troponin assay and are not interchangeable between manufacturers.
• A negative pathway argues against a heart attack, not against every serious cause of chest pain.
• Negative predictive value shifts with how common heart attacks are in the population being tested, so the same assay looks safer in a low-risk walk-in crowd than in a high-risk referral unit.

Why sixty minutes is enough#

Troponin is a protein released when heart muscle cells are damaged. For decades the assays that measured it were too coarse to pick up the trace amounts present in healthy blood, so clinicians had to wait three to six hours between samples for a rising level to become obvious. That wait was the bottleneck in every chest-pain workup.

High-sensitivity assays rebuilt the arithmetic. They detect troponin in nearly everyone, including healthy people, and they resolve small differences between two samples taken close together. That precision is the whole reason a change measured across a single hour can carry diagnostic weight. When the assay can distinguish a stable trace level from an early upward trend, the clock that used to run for half a day can run for sixty minutes instead.

The European Society of Cardiology 0/1-hour algorithm codifies this into a rule. A patient qualifies for rule-out through one of two routes: a single baseline value below a very low assay-specific cutoff in someone whose symptoms started more than three hours earlier, or a low baseline paired with a one-hour change beneath a small threshold. Rule-in fires when the baseline is clearly high or the one-hour rise is large. Because the exact numbers are set by each manufacturer and do not transfer between assays, a working pathway is always tied to one named assay in one laboratory.

What the 99 percent figures actually mean#

The number that sells these pathways is a negative predictive value close to 99.5 percent for acute myocardial infarction, with sensitivity in the same neighborhood. A 2020 systematic review and meta-analysis of the ESC 0/1-hour algorithm, pooling close to twenty thousand patients, reported sensitivity around 99 percent and a 30-day heart-attack rate under a tenth of a percent in the rule-out group. That combination is the evidence behind calling the rule-out zone safe.

Two qualifications belong right next to that headline.

First, negative predictive value is not a fixed property of the test. It climbs when disease is rare and sags when disease is common. The identical assay, run with the identical cutoffs, will post a more reassuring negative predictive value in a low-risk walk-in population than in a chest-pain unit crowded with high-risk transfers, so ask which population produced the number you were quoted. Sensitivity travels better between settings, which is why it is the fairer number to compare across studies. It is also, in effect, what the guideline anchors to when it treats a 30-day event rate under one percent as the definition of low risk.

Second, these numbers describe heart attacks and nothing else. A negative pathway does not exclude unstable angina, aortic dissection, or pulmonary embolism, all of which can present as chest pain and none of which a troponin trend is designed to catch. That is exactly why the algorithm never stands alone. It sits on top of an electrocardiogram and a careful history, and it informs a decision rather than making one.

What the evidence looks like in a real department#

Performance in a clean research dataset and performance in a busy emergency department are different questions, and the answer to the second one is more useful to you.

The ESC-TROP trial, published in the Journal of the American Heart Association in 2024, put the 0h/1h protocol up against a 0h/3h protocol across Swedish emergency departments. Among patients sent home after the 0h/1h protocol, the 30-day rate of heart attack or death was about 0.45 percent, statistically non-inferior to the 0.40 percent seen with the slower protocol and comfortably below the one percent low-risk ceiling. In the subgroup that met the low-risk troponin criteria and was discharged, only two of roughly 3,100 patients had a 30-day event, a rate near 0.06 percent.

The same trial is a useful antidote to overselling. Discharge rates rose only modestly, from about 67 to 70 percent, and the faster protocol did not actually shorten the length of stay in that setting. A quicker biomarker step compresses one part of the workup, but the total time from door to discharge still hinges on crowding, imaging, and the many downstream decisions a rapid troponin result cannot touch in your department. Speed on the protocol does not automatically translate into speed in the corridor.

How the guideline frames it#

The 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR chest-pain guideline named high-sensitivity troponin the preferred biomarker, endorsed a sex-specific 99th-percentile upper reference limit to define heart-muscle injury, and pushed clinicians toward validated decision pathways rather than lone stand-alone values. A 2022 Circulation analysis by Sandoval and colleagues examined how cleanly that guidance survives contact with the bedside and flagged the soft spots: the document names the pathways but leaves much of the operational detail, including which change thresholds and which observe-zone strategy to adopt, to each hospital. That gap is the practical lesson. A pathway is only as trustworthy as the specific assay, the validated cutoffs, and the patient mix you deploy it into.

How to read it as a patient or a colleague#

Treat the 99 percent figures as genuine but conditional, whichever side of the pathway you are on. They hold when the exact assay, the validated cutoffs, and a comparable patient population are all in place, and when the troponin result is weighed alongside the electrocardiogram and the story of the symptoms rather than on its own. A very low, unchanging high-sensitivity troponin is strong evidence against a heart attack as the cause of that particular episode. It is not a clean bill of cardiac health, and the people who arrive within the first hour or two of symptom onset are precisely the group where a single value is least reliable and the serial change earns its place.